title: Hyperthermic isolated perfusion with low-dose TNFalpha and doxorubicin in patients with locally advanced soft tissue limb sarcomas.
abstract: We report here the results of 27 patients who underwent hyperthermic isolated limb perfusion with low-dose TNFalpha (1 mg) and doxorubicin (8.5 mg/l of limb volume) for locally advanced soft tissue sarcomas. A tumor response was observed in 85% of cases. After a median follow-up of 30 months, limb salvage and local disease control were achieved in 82 and 85% of patients, respectively. Locoregional toxicity was low or mild in 14 patients, while 2 patients had severe limb toxicity. Systemic side effects were negligible. The perfusate/plasma area under the curve (AUC) ratio for TNFalpha was 56. HILP with low-dose TNFalpha and DXR proved to be an active neoadjuvant drug regimen against limb-threatening STS.
authors.affiliation: Clinica Chirurgica II, University of Padova, Italy. carlor.rossi@unipd.it
authors.forename: C R
authors.initials: CR
authors.lastname: Rossi
authors.forename: M
authors.initials: M
authors.lastname: Foletto
authors.forename: S
authors.initials: S
authors.lastname: Mocellin
authors.forename: P
authors.initials: P
authors.lastname: Pilati
authors.forename: L
authors.initials: L
authors.lastname: Quintieri
authors.forename: G L
authors.initials: GL
authors.lastname: De Salvo
authors.forename: D
authors.initials: D
authors.lastname: Nitti
authors.forename: M
authors.initials: M
authors.lastname: Lise
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D004317:Doxorubicin / Q000008:administration & dosage*; D005121:Extremities; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D014409:Tumor Necrosis Factor-alpha; D004317:Doxorubicin